MACOP-B Regimen Followed by Involved-Field Radiation Therapy in Early-Stage Aggressive Non-Hodgkin's Lymphoma Patients: 14-Year Update Results

References

• Vokes E. E., Ultmann J. E., Golomb H. M., et al. Long-term survival of patients with localized diffuse histiocytic lymphoma. J. Clin. Oncol. 1988; 3: 1309–1317
   Google Scholar
• Hallahan D. E., Farah R., Vokes E. E., et al. The patterns of failure in patients with pathological stage I and n diffuse histiocytic lymphoma treated with radiation therapy alone. Int. J. Radial. Oncol. Biol. Phys. 1999; 17: 767–771
   Google Scholar
• Landberg T. G., Hakansson L. G., Moller T. R., et al. CVP-remission-maintenance in stage I or n non-Hodgkin's lymphomas: preliminary results of a randomized study. Cancer 1979; 44: 831–838
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Bodey G. P., Freireich E. J., et al. Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer 1980; 46: 2356–2359
   PubMed Web of Science ®Google Scholar
• Nissen N. I., Ersboll J., Hansen H. S., et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer 1983; 52: 1–7
   PubMed Web of Science ®Google Scholar
• Miller T. P., Jones S. E. Initial chemotherapy for clinically localized lymphomas of unfavorable histology. Blood 1983; 62: 413–418
   PubMed Web of Science ®Google Scholar
• Connors J. M., Klimo P., Fairey R. N., Voss N. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann. Intern. Med. 1987; 107: 25–30
   PubMed Web of Science ®Google Scholar
• Jones S. E., Miller T. P., Connors J. M. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J. Clin. Oncol. 1989; 7: 1186–1191
   PubMed Web of Science ®Google Scholar
• Taylor R. E., Allan S. G., McIntyre M. A., et al. Influence of therapy on local control and survival in stage I and II intermediate and high grade non-Hodgkin's lymphoma. Eur. J. Cancer Clin, Oncol. 1988; 24: 1771–1777
   Google Scholar
• O'Connell M. J., Harrington D. P., Earle J. D., et al. Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage n aggressive histologic type non-Hodgkin's lymphoma. Cancer 1988; 61: 1754–1758
   PubMed Web of Science ®Google Scholar
• Tondini C., Zanini M., Lombardi F. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. J. Clin. Oncol. 1993; 11: 720–725
   PubMed Web of Science ®Google Scholar
• Longo D. L., Glatstein E., Duffey P. L., et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J. Clin. Oncol. 1989; 7: 1295–1302
   PubMed Web of Science ®Google Scholar
• Miller T. P., Dahlberg S., Cassady J. R., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N. Engl. J. Med. 1998; 339: 21–26
   PubMed Web of Science ®Google Scholar
• Harris N. L., Jaffe E. S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkins Disease Staging Classification. Cancer Res. 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Klimo P., Connors J. M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann. Intern. Med. 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Storti S., Zaccaria A., et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94: 33–38
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Non-parametric estimation from incomplete observation. J.A.M.A. 1958; 53: 457–468
   Web of Science ®Google Scholar
• Coiffier B., Haioun C., Ketterer N., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–1932
   PubMed Web of Science ®Google Scholar
• Witzig T. E., White C. A., Wiseman G. A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J. Clin.Oncol. 1999; 17: 3793–3803
   PubMed Web of Science ®Google Scholar